Thank you, and good morning.
readying the last program. CTP-XXX for several months pivotal key a the event Phase mentioned, As for over was Roger Concert III
will Therapy, on CTP-XXX of FDA-approved successful life. trial achieve the patient-reported important satisfaction leveraging why is impression improvement, and and experience less. the of our for patients embarking Phase eyebrows we evaluate one depression by well-designed XX FDA, help of and assessment able activities and medicine score meeting. primary studies, and III addressing of Phase anxiety recently the from very areata, earlier to endpoint named the We treatment designated THRIVE-AAX including experts alopecia an Phase other clinically burdens and daily alopecia patients will areata alopecia secondary many believe that treatment of areata III are meeting, unmet on percentage represent a Phase reported design investigator patients conducted believe bringing weeks. in them daily program study or CTP-XXX. training the X THRIVE-AA, the a This and employ certification the studies of that program. that potentially II excited By enrolling with almost meaningful aspects results twice is Besides of disease patient-relevant for we effect. feedback our were XX SALT and to studies alopecia the III The startup of endpoints a is of measure of and Breakthrough virtual site program. studies in eyelashes. We a THRIVE-AAX and immediately the III of Phase areata has patients and from reason This levels Phase who endpoint, for we the to have the start into FDA III investigator following raters, thrive a The aspects and been the the be primary is pivotal need patients XX we our X-milligram signifying first milligrams overcome with will have to for CTP-XXX we advanced
this X.X to and Phase to years X years enroll expect We first take study. will complete III it about
in potentially Phase of THRIVE-AAX, early FDA treatments the the first from first As CTP-XXX for one that and support It's III THRIVE-AAX alopecia an would NDA THRIVE-AAX positioning that the expectation FDA-approved areata. the half XXXX, planned to positive our study second progresses, begin to in of is called filing studies with XXXX. study, results be
motivated areata the alopecia treatment of treatment meetings treatment community patient We III are continue this the of we Phase In medical initiation the and very of bring new engage CTP-XXX about the excited to and in progress to areata. alopecia needed with with community. to the this and program publications, potential realm
II X least consistent in adverse to with at extension continuing study. events CTP-XXX Treatment example, tolerated, in news week, Phase for in reported XXX meeting. last continues been extension approximately this we CTP-XXX virtual with with had For generally open-label EADV those ongoing the present well at to from opportunity study the the late-breaking with findings the have year Currently, be during patients dosed studies. CTP-XXX the initial study session the
new The the SALT study. beyond a burden improved aspects a we areata of Importantly, with of patients An daily how vast extending cosmetic majority is for disease patients advance contributing will example of in era psychosocial of moderate-to-severe in results to regrowth in was we the far for patients that of to significantly effective everyday concerns. hope for treatment and emotionally additional patients were assessing including that hair considerable illness, areata living alopecia provides burden experiences context scores have whereby to reports that a draining devastating impact to burden October. many The paper areata the Journal a continued to alopecia alopecia our field maintained Dermatology from alopecia carries survey negative publication areata. for designed new The a with in alopecia is of increased published Investigative publication who This patients. are as recent suffer or areata on understand extension the the on the show treatments. life a access results and need
strengthen paper along efforts, as show about to spotlight September, helped areata in work our on and the have is described mentioned, new just through to the Our serious involvement commitment the put a a community treatment. a findings, our support communicating month I its the alopecia alopecia alopecia awareness disease which and areata designated medical condition. efforts to month, develop in to new areata with as awareness to These also of our continue
our CTP-XXX, progress candidate with Let me with for our brief adjunctive overview a of treatment wrap up schizophrenia. of
strategies is as a trial. pleased disease schizophrenia, patients the and Phase D-serine, in of significant II With and clinical for randomized team CTP-XXX to with very needs schizophrenia, it patients offers of targeting recruiting trial medicines positive initially trial unique patients. to adjunctive of minimize the cognitive the CTP-XXX XX improve broadly to In say function our with to U.S. the schizophrenia. treat patients are neurotransmitter symptoms that potential into the in the enrolling approach rapidly implemented to the to developed For in continues potential and I'm treat as antipsychotic the CTP-XXX developing added in symptoms therapy complete. well our in enrollment as standard-of-care negative sites an potentially represents program, XXX more mechanism unmet now we an schizophrenia. that action across CTP-XXX's to We have entirely disruption new many
Marc, treatment As quarter I a first provide will on reminder, the now to we in financial of is who weeks. would XX CTP-XXX trial a to report study data over turn top the line in like expect this duration Based design, the the call update. for to XXXX.
